about
Botulinum toxin type B for cervical dystoniaBioterrorism and the Role of the Clinical Microbiology LaboratorySporicidal performance induced by photocatalytic production of organic peroxide under visible light irradiationBotulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chainUnderstanding of skeletal deformities in Parkinson's disease.Clinical study of botulinum toxin A injection combined with spasmodic muscle therapeutic instrument on lower limb spasticity in patients with stroke.Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells.Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study.SNARE tagging allows stepwise assembly of a multimodular medicinal toxin.Emerging drugs in Tourette syndrome.Botulinum toxin therapy for cervical dystonia: the science of dosingEmbryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discoveryAggregatibacter actinomycetemcomitans leukotoxin: from threat to therapyCreating and virtually screening databases of fluorescently-labelled compounds for the discovery of target-specific molecular probes.A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteinsSafety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical TrialEfficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis.Clinical Effect of Endoscopic Pneumatic Dilation for AchalasiaNewly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays.Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins--a single cohort 4-year follow-up study.Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correctionBotulinum toxin type A induces changes in the chemical coding of substance P-immunoreactive dorsal root ganglia sensory neurons supplying the porcine urinary bladderClinical uses of botulinum neurotoxins: current indications, limitations and future developmentsTreatment of symptoms in multiple sclerosis.Migraine: emerging treatment options for preventive and acute attack therapy.Long-term efficacy and safety of botulinum toxin injections in dystonia.Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strengthBotulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion.Botulinum toxin injection to facilitate rehabilitation of muscle imbalance syndromes in sports medicine.Botulinum Toxin A Injection into the Subscapularis Muscle to Treat Intractable Hemiplegic Shoulder Pain.Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons.Clostridial toxins.Embryonic Stem Cell-Derived Neurons Grown on Multi-Electrode Arrays as a Novel In vitro Bioassay for the Detection of Clostridium botulinum Neurotoxins.The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limbBotox(®) to reduce drooling in a paediatric population with neurological impairments: a Phase I study.Targeted secretion inhibitors-innovative protein therapeutics
P2860
Q24185766-CD1674F9-EA1C-4339-AF03-0E778E73D17CQ28388247-AF72572F-1A92-4617-A4D9-7CCAAE3B54F3Q28829094-868A4A7C-32CD-4E1D-921A-03F93E31FD8DQ33301010-22C6BDA7-22AC-4F89-9944-A9E6210D2485Q33568833-7BBF87FB-6681-4B3C-8073-17BA812D7506Q33744237-1EE40611-41F1-4AA8-AAFD-D2816D8B2DCDQ33808241-13FDAFFA-5C05-43C7-B012-447AB75E9070Q34067456-99733134-D285-44F7-AFE4-A0926AED352AQ34154494-3F8846A4-FF90-4072-A866-B28F813AEB24Q34241315-42B90C77-DD8D-4751-8C4B-6BEFE1639E64Q34423658-BC0C5169-655A-430C-AAF7-E69B21DA929CQ34518731-4913F186-E4CF-44D4-B6DB-F21FC11A4BFEQ34850583-F4AE1EA8-3A7A-470C-A72D-9256C66C75A0Q35129153-C7B69147-02F8-4F45-BD63-3DDF6A3A4B29Q35230342-9835F23A-1396-4447-A11D-3356E4F756BDQ35626894-FAF30915-5586-4B68-AC1C-E64BEA1FB636Q35681898-A1D9ACCE-7995-490C-8476-21F3B959CCDEQ35962741-774185C0-8088-4671-860E-2CA91E05BE54Q36006813-2AA4DFD4-A24E-4669-9A95-2937E41FDE52Q36196546-87A34068-0FCB-4933-939C-E066FBDB3681Q36223269-9BB153F7-08CD-4095-BD81-A48370F097CAQ36254051-A47BF0C1-68E9-48DC-87C1-A70FA0F41883Q36294582-36C5B530-C8ED-42CF-AE0F-4398EB075538Q36329632-CF0B96E2-E2EB-44D2-916D-272630912867Q36395728-77AF26AF-A813-4ED8-9EF4-5638BD736BBDQ36474348-7198CF8F-2539-4BE1-BE5B-5F444590A5A9Q36580576-2EF846CA-7CA4-476E-9B8A-3E89BF1F20D4Q36807185-69316132-564A-459F-8765-783A9EC2EC4EQ36847246-AD3ADA65-115C-4F1B-A347-A0A549DD26B0Q36895179-705B6701-B197-42A4-938F-0C048896A54DQ36913556-426CB3EB-C2F5-4BA3-9A7A-DECCDABB5842Q36938468-BBF1FF57-4297-4ABF-926F-798051B7E229Q37011533-7105DA22-1709-4262-ACA2-5A1B20DE962DQ37235422-6DC6A125-5C8A-4873-A073-B49C238CD7B6Q37237111-A3397A78-1A8C-4D52-BA2C-6539C541B981Q37613674-BB8BDFDF-6602-482D-9591-A6786779A53AQ37660850-2AAED60F-F069-48F6-8742-ACA0C382F007Q37883035-06FD22F9-F43F-4430-BBB0-A78105637543Q37928736-0F958F93-83EE-4E2A-AAE8-41BFAC0E232BQ37954277-73937928-2A78-4D38-9281-F0FB2CAA0FC2
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Botulinum toxin in clinical practice
@ast
Botulinum toxin in clinical practice
@en
type
label
Botulinum toxin in clinical practice
@ast
Botulinum toxin in clinical practice
@en
prefLabel
Botulinum toxin in clinical practice
@ast
Botulinum toxin in clinical practice
@en
P2860
P356
P1476
Botulinum toxin in clinical practice
@en
P2093
Jankovic J
P2860
P304
P356
10.1136/JNNP.2003.034702
P407
P577
2004-07-01T00:00:00Z